Publications and Presentations
Diagnostic Criteria for Hereditary Non-Polyposis Colorectal Cancer and Microsatellite Instability: The Revised Bethesda Guidelines
Barrett's Esophagus Working Group (pdf, 157kb)
2008 Publications
Kendall BJ, Macdonald GA, Hayward NK, Prins JB, Brown I, Walker N, Pandeya N, Green AC, Webb PM, Whiteman DC; Study of Digestive Health.
Leptin and the risk of Barrett's oesophagus. Gut. 2008 Apr;57(4):448-54. Epub 2008 Jan 4.
Ross, S., Milner, J., & Umar, A. Role of Epigenetics and Nutrition in Cancer Prevention. J. Nutrition 2008. In press.
Sato F, Jin Z, Schulmann K, Wang J, Greenwald BD, Ito T, Kan T, Hamilton JP, Yang J, Paun B, David S, Olaru A, Cheng Y, Mori Y, Abraham JM, Yfantis HG, Wu TT, Fredericksen MB, Wang KK, Canto M, Romero Y, Feng Z, Meltzer SJ. Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS ONE. 2008 Apr 2;3(4):e1890.
Schoen, R. E., Mutch, M. M, Fleshman, J., Rall, C.,, Dry, S., Seligson, S., Umar, A., & Pinsky, P. 2008 Prevalence of Aberrant Crypt Foci: An ancillary study to the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. Gastrointestinal Endoscopy 2008 Jan 4 [Epub ahead of print].
Soballe PW, Rodriguez L M, Cruess DF, Cash BD, DeNobile JW, Kirsch IR. Colonoscopic Removal of Aberrant Crypt Foci: a Prospective, Randomized, Blinded Trial (Submitted).
Zuo X, Shen L, Issa JP, Moy O, Morris JS, Lippman SM, Shureiqi I. 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation. FASEB J. 2008 Jan 15; [Epub ahead of print].
2007 Publications
Brenner BM, Stoler DL,Rodriguez L, Karpenko MJ, Swede H, Petrelli NJ, Anderson GR. Allelic Losses at Genomic instability-associated Loci in villous adenoma and adjacent colorectal cancers. Cancer Genet Cytogenet. 2007 April 1; 174(1):9-15.
Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, Ayub K, Rabinovitch PS, Vaughan TL, Reid BJ. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007 Feb;4(2):e67.
Gerner EW, Meyskens FL Jr, Goldschmid S, Lance P, Pelot D. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. Amino Acids. 2007 Aug;33(2):189-95. Epub 2007 Mar 30.
Heath, E. I., Canto, M. I., Piantadosi, S., Montgomery, E., Weinstein, W. M., Herman, J. G., Dannenberg, A. J., Yang, V. W., Shar, A. O., Hawk, E., Forastiere, A. A. Chemoprevention for Barrett's Esophagus Trial Research Group. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007 Apr 4;99(7):545-57.
Larghi A, Lightdale CJ, Ross AS, Fedi P, Hart J, Rotterdam H, Noffsinger A, Memeo L, Bhagat G, Waxman I. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy. 2007 Dec;39(12):1086-91. Epub 2007 Aug 15.
Overholt BF, Wang KK, Burdick JS, Lightdale CJ, Kimmey M, Nava HR, Sivak MV Jr, Nishioka N, Barr H, Marcon N, Pedrosa M, Bronner MP, Grace M, Depot M; International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc. 2007 Sep;66(3):460-8. Epub 2007 Jul 23.
Risques RA, Vaughan TL, Li X, Odze RD, Blount PL, Ayub K, Gallaher JL, Reid BJ, Rabinovitch PS. Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2649-55.
Stillman, J. S., Kauff, N., Close, G., Zauber, A. G., Winawer, S. J. The importance of identifying high risk patients in a feneral screening colonoscopy population: results from the national colonoscopy study pedigree analysis. Digestive Disease Week 2007.
Tang L, Guan H, Ding X, Wang JS. Modulation of aflatoxin toxicity and biomarkers by lycopene in F344 rats. Toxicol Appl Pharmacol. 2007 Feb 15;219(1):10-7. Epub 2006 Dec 6.
Umar A., Richmond E., Griebel, D. J. Colorectal Cancer Prevention: Diet, Drugs or Nothing, 2007 Colorectal Cancer Reports 3(1)16-23.
Umar, A., Richmond, E., & Griebel, D. Colorectal Cancer Prevention: Diet, Drugs, or Nothing Current Colorectal Cancer Reports 2007, 3:16–23.
2006 Publications
Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31;355(9):873-84.
Buchanan, F. G., and DuBois, R. N. (2006). Connecting COX-2 and Wnt in cancer. Cancer Cell 9, 6-8.
Buchanan, F. G., and DuBois, R. N. (2006). Emerging roles of beta-arrestins. Cell Cycle 5, 2060-2063.
Buchanan, F. G., Gorden, D. L, Matta, P., Shi, Q., Matrisian, L. M., and DuBois, R. N. (2006). Role of betaarrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A 103,1492-1497.
Cha, Y. I., Kim, S. H., Sepich, D., Buchanan, F. G., Solnica-Krezel, L., and DuBois, R. N. (2006). Cyclooxygenase-1-derived PGE2 promotes cell motility via the G-protein-coupled EP4 receptor during vertebrate gastrulation. Genes Dev 20, 77-86.
Glebov OK , Rodriguez LM, Lynch P, Patterson S, Lynch H, Nakahara K, Jenkins J, Cliatt J, Humbyrd C-J, DeNobile J, Soballe PW, Gallinger S, Buchbinder A, Gordon G, Hawk ET, Kirsch IR. Celecoxib Treatment Alters the Gene Expression Profile of Normal Colonic Mucosa. Cancer Epidemiology Biomarkers & Prevention: July 2006.
Glebov OK , Rodriguez LM, Soballe PW, DeNobile J, Cliatt J, Nakahara K, Kirsch IR. Gene Expression Patterns Distinguish Colonscopically Isolated Human Aberrant Crypt Foci from Normal Colonic Mucosa. 2006 Cancer Epidemiology Biomarkers & Prevention:Nov 2006.
Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Taylor PR, Limburg PJ, Dawsey SM, Hawk ET, Qiao YL, Kirsch IR. Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res. 2006 Jul 1;66(13):6851-60.
Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Taylor PR, Limburg PJ, Dawsey SM, Hawk ET, Qiao YL, Kirsch IR. Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1046-7.
Kann L, James Han1, David Ahlquist2, Theodore Levin3, Douglas Rex4, Duncan Whitney1,1, Sanford Markowitz5 and Anthony Shuber Improved Marker Combination for Detection of De Novo Genetic Variation and Aberrant DNA in Colorectal Neoplasia Clinical Chemistry 52: 2299-2302, 2006. First published November 2, 2006; 10.1373/clinchem.2007.070896.
Komatsu, K., Buchanan, F. G., Otaka, M., Jin, M., Odashima, M., Horikawa, Y., Watanabe, S., and Dubois, R. N. (2006). Gene expression profiling following constitutive activation of MEK1 and transformation of rat intestinal epithelial cells. Mol Cancer 5, 63.
Luo, H., Cox, S. B., Gao, W., Yu, J., Tang, L. & Wang J.-S Metabolic profiling in validation of plasma biomarkers for green tea polyphenols. Metabolomics, 2006 2:235.
Mann, J. R., Backlund, M. G., Buchanan, F. G., Daikoku, T., Holla, V. R., Rosenberg, D. W., Dey, S. K., and DuBois, R. N. (2006). Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res 66, 6649-6656.
Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J; APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006 Sep 5;114(10):1028-35.
Umar A. Lynch syndrome (HNPCC) and microsatellite instability analysis guidelines. Cancer Biomarkers 2006; 2:1-4.
Umar, A. NCI Committed to Colorectal Cancer Prevention, Guest Update for Director’s Update NCI Cancer Bulletin, 2006; 3(34):1-2.
Wang, D., Wang, H., Quo, Y., Ning, W., Katkuri, S., Wahli, W., Desvergne, B., Dey, S. K., and DuBois, R. N. (2006). Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A 103, 19069-19074.
Wang, D., Wang, H., Brown, J., Daikoku, T., Ning, W., Shi, Q., Richmond, A., Strieter, R., Dey, S. K., and DuBois, R. N. (2006). CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J ExpMed 203, 941-951.
Xu, L., Tang, L., Yu, J. & Wang J. –S. Hepatitis B viru genotypes and 1762T/1764A double mutations and risk of hepatocellular carcinoma in southern Guangxi, China. Proc AACR 2006, 48:1736.
2005 Publications
Hawk, E. and J. L. Viner (2005). "The critical role of risk-benefit assessments in cancer prevention." Cancer Epidemiol Biomarkers Prev 14(2): 297-8.
Hawk, E. and J. L. Viner (2005). "Statins and cancer--beyond the "one drug, one disease" model." N Engl J Med 352(21): 2238-9.
Hawk, E. T., A. Umar, et al. (2005). "Can animal models help us select specific compounds for cancer prevention trials?" Recent Results Cancer Res 166: 71-87.
Hawk, E. T., A. Umar, et al. (2005). "Prevention and therapy of colorectal cancer." Med Clin North Am 89(1): 85-110, viii.
Risinger, J. I., G. L. Maxwell, et al. (2005). "Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling." Cancer Res 65(12): 5031-7.
Smith KJ, O'Brien SM, Smithers BM, Gotley DC, Webb PM, Green AC, Whiteman DC. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2481-6.
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17;352(11):1071-80. Epub 2005 Feb 15.
Umar, A., C. A. Berrevoets, et al. (2005). "Functional analysis of a novel androgen receptor mutation, Q902K, in an individual with partial androgen insensitivity." J Clin Endocrinol Metab 90(1): 507-15.
Back to Top
2004 Publications
Forman, M. R., S. D. Hursting, et al. (2004). "Nutrition and cancer prevention: a multidisciplinary perspective on human trials." Annu Rev Nutr 24: 223-54.
Hawk, E. T., A. Umar, et al. (2004). "Colorectal cancer chemoprevention--an overview of the science." Gastroenterology 126(5): 1423-47.
Kapetanovic, I. M., A. Umar, et al. (2004). "Proceedings: the Applications of Bioinformatics in Cancer Detection Workshop." Ann N Y Acad Sci 1020: 1-9.
Lao, C. D., P. Backoff, et al. (2004). "Irreversible ototoxicity associated with difluoromethylornithine." Cancer Epidemiol Biomarkers Prev 13(7): 1250-2.
Lin, D. P., Y. Wang, et al. (2004). "An Msh2 point mutation uncouples DNA mismatch repair and apoptosis." Cancer Res 64(2): 517-22.
Lu, Q., Y. T. Yang, et al. (2004). "Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors." J Med Chem 47(2): 467-74.
Pereira, M. A., L. Tao, et al. (2004). "Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors." Carcinogenesis 25(10): 1917-23.
Umar, A. (2004). "Applications of bioinformatics in cancer detection: a lexicon of bioinformatics terms." Ann N Y Acad Sci 1020: 263-76.
Umar, A. (2004). "Lynch syndrome (HNPCC) and microsatellite instability." Dis Markers 20(4-5): 179-80.
Umar, A., M. Boisseau, et al. (2004). "Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model." Fundam Clin Pharmacol 18(5): 559-63.
Umar, A., C. R. Boland, et al. (2004). "Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability." J Natl Cancer Inst 96(4): 261-8.
Umar, A., J. I. Risinger, et al. (2004). "Testing guidelines for hereditary non-polyposis colorectal cancer." Nat Rev Cancer 4(2): 153-8.
Umar, A. and S. Srivastava (2004). "The promise of biomarkers in colorectal cancer detection." Dis Markers 20(2): 87-96.
Xiao, Z., B. T. Luke, et al. (2004). "Serum proteomic profiles suggest celecoxib-modulated targets and response predictors." Cancer Res 64(8): 2904-9.
Back to Top
2003 Publications
Dunn BK, Verma M, Umar A. Epigenetics in cancer prevention: early detection and risk assessment: introduction. Ann N Y Acad Sci. 2003, 983:1-4.
Fischer SM, Conti CJ, Viner JL, Aldaz CM, and Lubet RA. Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis. 2003 May;24(5):945-52.
Glebov OK , Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, DeNobile J, Soballe PW, Simon R, Wright G, Lynch P, Patterson S, Lynch H, Gallinger S, Buchbinder A, Gordon G, Hawk ET, Kirsch IR. Distinguishing Right from Left Colon by The Pattern of Gene Expression.2003. Cancer Epidemiology Biomarkers & Prevention: Vol.12, 775-7762, August 2003.
Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd C-J, DeNobile J, Soballe P, Simon R, Wright G, Lynch P, Patterson S, Lynch H, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR: Distinguishing right from left colon by the pattern of gene expression. Cancer Epi Biomark Prev 12:755-762, 2003.
Hawk E: COX-2 in cancer. In Ravnetrykk - Targeted Cancer Therapies, An Odyssey. (Bruland ØS, Flægstad T, eds.), 2003, Tromso University Press, Tromso, pp. 92-95.
Hawk E, Sigman CC, Kelloff G: Prevention of gastrointestinal cancers. In Gastrointestinal Oncology. (Rustgi A, ed.), 2003, Saunders, Edinburgh, pp. 205-214.
Hawk ET, Viner JL, and Umar A. Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials. Prog Exp Tum Res. 2003;37: 210-42.
Hawk E, Viner JL, Umar A, Anderson WF, Sigman C, Guyton KZ: Cancer and the cyclooxygenase enzyme - Implications for prevention and treatment. Amer J Cancer 2:27-55, 2003.
Hawk ET and Viner JL. Aspirin: still learning about the wonder drug. Gut 2003; 52(11): 1535-36.
Kelloff GJ, O'Shaughnessy JA, Gordon GB, Hawk ET, Sigman CC: Counterpoint - Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 12:593-596, 2003.
Linden KG, Carpenter PM, McLaren CE, Barr RJ, Hite P, Sun JD, Li KT, Viner JL, and Meyskens FL. Chemoprevention of non-melanoma skin cancer: experience with a polyphenol from green tea. Recent Results Cancer Res. 2003;163: 165-71.
Patel A, Groopman JD, Umar A. DNA methylation as a cancer-specific biomarker: from molecules to populations. Ann N Y Acad Sci. 2003 Mar;983:286-97.
Richmond E and Viner JL. Chemoprevention of skin cancer. Semin Oncol Nurs. 2003 Feb;19(1):62-9.
Sabichi AL, Demierre MF, Hawk ET, Lerman CE, Lippman SM: Frontiers in cancer prevention research. Cancer Res 63:5649-5655, 2003.
Shotland LI, Viner JL, Ondrey FG, Dobie RA, Oeffinger KC and Schwartz CL. Monitoring for ototoxicity in cancer clinical trials. Audiology Today 2003;15(4):11-13.
Steele VE, Hawk ET, Viner JL, and Lubet RA. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res. 2003 Feb;523-524:137-44.
Verma M, Dunn BK, Ross S, Jain P, Wang W, Hayes R, Umar A. Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigenetics in Cancer Prevention. Ann N Y Acad Sci. 2003 Mar;983:298-319.
Umar A, Viner JL, Anderson WF, and Hawk E. Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol 2003;26(4):S48-57.
Watson AJM, Hawk E, DuBois RN: Chemoprevention of colorectal cancer. In Gastrointestinal Oncology. (Rustgi A, ed.), 2003, Saunders, Edinburgh, pp. 421-428.
Back to Top
2002 Publications
Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des 8:1035-62, 2002.
[Abstract on PubMed]
Chu KC, Anderson WF. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Ca Res & Treatment 74:199-211, 2002.
Hawk ET, Viner JL, Dannenberg AJ, DuBois RN. COX-2 in cancer - a player that's defining the rules. (Editorial) J Natl Cancer Inst 94:545-546, 2002.
[Abstract on PubMed]
Phillips RKS, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, et al: A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857-860, 2002.
[Abstract on PubMed]
Umar A, Viner JL, Hawk E. The future of colorectal cancer prevention. Ann NY Acad Sci 952:88-108, 2002.
[Abstract on PubMed]
Umar A, Viner JL, Richmond E, Anderson WF, Hawk E. Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol 7:2-26, 2002.
[Abstract on PubMed]
Viner J, Lawrence J, Richmond E, Hawk E. Cancer chemoprevention. In Cancer Handbook. MacMillan Publishers, Hampshire; chapter 90. (Alison MR, Weinberg R, Shay J, Liotta L, eds.), 2002.
Back to Top
2001 Publications
Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol. 2001 Jan 1;19(1):18-27
[Abstract on PubMed]
Anderson WF, Hawk E, Berg CD. Secondary chemoprevention of upper aerodigestive tract tumors. Semin Oncol 2001;28:106-20.
[Abstract on PubMed]
Canto MT, Anderson WF, Brawley OW: Geographic variation in breast cancer mortality for white and black women: 1986-1995. CA-A Cancer Journal For Clinicians 51:367-370, 2001.
[Abstract on PubMed]
Chu KC, Anderson WF, Fritz A, et al. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 92:37-45, 2001.
[Abstract on PubMed]
Dimitrov NV, Leece CM, Seymour EM, Bermink M, Gardiner J, Tompkins ER, Hawk E, Nashawaty M, Crowell J, Bennett JL: Oltipraz concentrations in plasma, buccal mucosa cells, and lipids - pharmacological studies. Cancer Epi Biomark Prev 10:201-208, 2001.
[Abstract on PubMed]
Hawk E, Viner JL: Chemoprevention in ulcerative colitis - narrowing the gap between clinical practice and research. Annals Int Med 134:158-160, 2001.
[Abstract on PubMed]
Hawk ET, Viner JL, Anderson BF: Development of COX inhibitors as cancer chemopreventives. ASCO Educational Book pp.28-37, Spring, 2001.
Kelloff GJ, Sigman CC, Hawk ET, Johnson KM, Crowell JA, Guyton KZ: Surrogate end-point biomarkers in chemopreventive drug development. IARC Sci Publ 154:13-26, 2001.
[Abstract on PubMed]
Shotland LI, Ondrey FG, Mayo KA, Viner JL. Recommendations for cancer prevention trials using potentially ototoxic test agents. J Clin Oncol 19:1658-63, 2001.
[Abstract on PubMed]
Back to Top
2000 Publications
Anderson WF, Hawk E, Berg CD. Secondary chemoprevention of upper aerodigestive tract tumors. Semin Oncol. 2001 Feb;28(1):106-20.
[Abstract on PubMed]
Anderson WF, Reeves JE, Elias A, Berkel H.: Outcome of patients with metastatic breast carcinoma treated at a private medical oncology clinic. Cancer 66(1):95-107, 2000.
[Abstract on PubMed]
Edelmann, W, Umar, A, Yang, K., Heyer, J, Kucherlapati, M, Lia, M, Kneitz, B, Avdievich, E, Wong, E, Kunkel, TA, Lipkin, M, Crouse, G, Kolodner, R, and Kucherlapati, R: The DNA mismatch repair gene MSH3 is cooperating in tumor suppression. Cancer Research. 60:803-807, 2000.
[Abstract on PubMed]
Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, and I Pastan: Antitumor activity of K1LysPE38QQR, an immunotoxin that targets mesothelin, a cell-surface antigen overexpressed in ovarian cancer and mesothelioma. J Immunotherapy 23(4):473-479, 2000.
[Abstract on PubMed
Hawk E, Breslow RA, Graubard B: Male pattern baldness and clinical prostate cancer in the Epidemiologic Follow-up Study of the First National Health and Nutrition Examination Survey. Cancer Epi Biomark Prev 9:523-527, 2000.
[Abstract on PubMed]
Hawk E, Lippman S: Primary cancer prevention studies. Hematol Oncol Clin North Am 14:809-830, 2000.
[Abstract on PubMed]
Hawk ET, Viner JL.Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research. Ann Intern Med. 2001 Jan 16;134(2):158-60.
[Abstract on PubMed]
Hawk E, Viner J, Lawrence J: Biomarkers as surrogates for cancer development. Current Oncol Reports 2:1-9, 2000.
[Abstract on PubMed]
Heath E, Limburg P, Hawk E, Forastiere A: Adenocarcinoma of the esophagus: risk factors and prevention. Oncology 14:507-514, 2000.
[Abstract on PubMed]
Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk E, Lubet RA: Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res, 60:1864-1870, 2000.
[Abstract on PubMed]
Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC: Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 130(2S Suppl):467S?471S, 2000.
[Abstract on PubMed]
Kelloff GJ, Sigman CC, Hawk ET, Johnson KM, Crowell JA, Guyton KZ. Surrogate end-point biomarkers in chemopreventive drug development. IARC Sci Publ. 2001;154:13-26.
[Abstract on PubMed]
Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA: Perspectives on surrogate endpoints in the development of drugs that reduce the risk of cancer. Cancer Epi Biomark Prev 9:127-127, 2000.
[Abstract on PubMed]
Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, et al: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18:3964-73, 2000.
[Abstract on PubMed]
Shinohara H, Fan D, Ozawa S, Yano S, van Arsdell M, Viner JL, Beers R, Pastan I, and IJ Fidler: Site specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin. Int J Oncol 17:643-651, 2000.
[Abstract on PubMed]
Shotland LI, Ondrey FG, Mayo KA, Viner JL. Recommendations for cancer prevention trials using potentially ototoxic test agents. J Clin Oncol. 2001 Mar 15;19(6):1658-63.
[Abstract on PubMed]
Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, et al: Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs 9:2121-2138, 2000.
[Abstract on PubMed]
Steinbach G, Lynch PM, Phillips R, Wallace M, Hawk E, Gordon G, Sherman J, et al: A randomized, double-blind placebo controlled study of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952, 2000.
[Abstract on PubMed]
van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Kresty L, Kemmenoe BH, Elson P, Rybicki L, Church J, Provencher K, McLain D, Hawk E, Fryer B, Kelloff G, Ganapathi R, Budd GT: Phase I trial of Exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with Familial Adenomatous Polyposis. Clin Cancer Res, 6:78-89, 2000.
[Abstract on PubMed]
Watanabe Y, Haugen-Strano A, Umar A, Yamada K, Hemmi H, Kikuchi Y, Takano S, Shibata Y, Barrett JC, Kunkel TA, Koi M: Complementation of an hMSH2 defect in human colorectal carcinoma cells by human chromosome 2 transfer. Mol. Carcinog. 29:37-49, 2000.
[Abstract on PubMed]
Back to Top
